Clinical Trial Detail

NCT ID NCT02076191
Title Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors John Mascarenhas
Indications

bone marrow cancer

Therapies

Decitabine + Ruxolitinib

Age Groups: adult

No variant requirements are available.